

Queensland and Northern Territory

ANTIFUNGAL USAGE – STATEWIDE BENCHMARKING REPORT

July – December 2023

Antifungal utilisation rates provided in this report are calculated using the number of defined daily doses (DDDs) of the antimicrobial class consumed per 1,000 occupied bed days (OBD). Usage rates represent total inpatient usage in the acute hospital setting, excluding emergency departments and operating theatres.

Contributing hospitals can find their de-identifying code via the NAUSP Portal 'Maintain My Hospital' drop-down menu.

Usage rates for antifungal agents are highly dependent on the casemix of the hospital, including whether the hospital provides transplant or haematology/oncology services. Usage of systemic antifungals is typically higher in larger hospitals, particularly Principal Referral hospitals. Usage rates reflect the quantity of antimicrobials dispensed from pharmacy and not actual consumption at patient level.


Contributing hospitals are assigned to Australian Institute for Health and Welfare (AIHW) defined peer groups.¹ [Note: Public and private acute group C and D hospitals have negligible systemic antifungal use and are excluded from this report].

DDD values for each antimicrobial are assigned by the World Health Organization (WHO) based on the "assumed average maintenance dose per day for the main indication in adults". DDDs are reviewed annually by the WHO as dosing recommendations change over time. For more information refer to: https://www.whooc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system/

The chart below presents aggregated antifungal data for the six-month period from 1 July 2023 to 31 December 2023. Unless otherwise specified, the aggregate rates include all acute care areas of the hospital, excluding usage in the emergency department and the operating theatre.

¹ AIHW. *Hospital resources 2017-18: Australian hospital statistics*. Available from <https://www.aihw.gov.au/reports/hospitals/hospital-resources-2017-18-ahs/data>

Chart 1: Total acute hospital antifungal usage rates (DDD/1,000 OBD) in NAUSP contributor hospitals, by peer group, Queensland and Northern Territory, July-December 2023 (excluding emergency and theatre)



*Other = flucytosine, griseofulvin, isavuconazole, ketoconazole and terbinafine.

This report includes data from 30 hospitals in QLD and NT:

Alice Springs Hospital	Mt Isa Hospital
Buderim Private Hospital	Nambour General Hospital
Bundaberg Hospital	Pindara Private Hospital
Caboolture Hospital	Queen Elizabeth 2 Jubilee Hospital
Gold Coast Private Hospital	Redcliffe Hospital
Greenslopes Hospital	Redland Hospital
Gympie Health Service	Royal Brisbane And Women's Hospital
Hervey Bay Hospital	St Andrew's War Memorial Hospital
Ipswich Hospital	St Vincent's Private Hospital Northside
John Flynn Private Hospital	St Vincent's Private Hospital Toowoomba
Mackay Base Hospital	Sunshine Coast University Hospital
Maryborough Hospital	The Prince Charles Hospital
Mater Hospital Brisbane	Toowoomba Hospital
Mater Private Hospital Brisbane	Townsville Hospital
Mater Private Hospital Springfield	Wesley Hospital

Disclaimer:

Data presented in this report were correct at the time of publication. As additional hospitals join NAUSP, retrospective data are included. Data may change when quality assurance processes identify the need for data updates.

The National Antimicrobial Utilisation Surveillance Program (NAUSP) is funded by the Commonwealth Department of Health and Aged Care. NAUSP is administered by Antimicrobial Programs, Communicable Disease Control Branch, Department for Health and Wellbeing, Government of South Australia. All individual hospital data contributed to this program will remain de-identified unless otherwise agreed in writing. Aggregated data may be provided to all contributors, the ACSQHC and the Commonwealth.